BillionToOne is widely regarded as an innovative, fast-growing molecular diagnostics and precision health company specializing in advanced prenatal screening and oncology liquid biopsy testing.

BillionToOne's mission is centered on democratizing access to precision molecular diagnostics by engineering advanced testing platforms that are exceptionally accurate, fast, scalable, and affordable across healthcare systems.

BillionToOne is a precision diagnostics company that utilizes a proprietary "molecular counter" platform to detect DNA molecules at a single-count level.

American Express Membership Rewards points possess a flexible valuation that varies significantly depending on how you choose to redeem them, meaning their cash value is not a fixed amount.

Bitdeer Technologies Group commands a corporate market capitalization of approximately $2.81 billion USD.

BillionToOne is a molecular diagnostics enterprise that develops advanced, highly sensitive test technologies capable of analyzing DNA molecules down to single-nucleotide precision.

Yes, clinical tests offered by BillionToOne—such as its UNITY prenatal screen and Northstar oncology liquid biopsy panels—are widely covered by Medicare, Medicaid, and major private commercial health insurance providers.

Financial tracking of BillionToOne encompasses private venture capital valuations and specialized biotech market metrics.

BLLN is the ticker symbol for BillionToOne Inc., a molecular diagnostics company.

BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, United States.

Yes, BillionToOne operates as a publicly traded enterprise. The molecular diagnostics and precision medicine company successfully completed its initial public offering on the NASDAQ Global Select Market, trading under the ticker symbol BLLN.

BillionToOne has evolved past its early-stage startup origins into a publicly traded commercial-stage molecular diagnostics enterprise.